logo
logo

Accellix, the Cell Therapy QC Company Raises $9.5 Million Series D Round

Jun 11, 2020•over 5 years ago

Amount Raised

$9 Million

Round Type

series d

Description

Today Accellix, the Cell Therapy QC company, announced a Series D financing round of $9.5 million led by bioMérieux, a world leader in the field of in vitro diagnostics for over 55 years. All existing major investors participated in this raise and have also agreed to convert their pre-existing convertible note in the amount of $8.5 million, bringing the company's total funding in this round to $18 million. This latest round of funding will be used to further expand the market reach of the Accellix system for Cell Therapy QC, enabling its customers greater access to the expertise, scale, resources, and technology needed to effectively assess the quality of life saving immunotherapies.

Company Information

Company

About

AccelFoods is an early-stage venture fund investing in consumer products. We partner with entrepreneurs to bring innovative, high-quality food and beverage products to the forefront of the industry and create the next generation of enduring brands. With nearly $40m under management, we are hands-on partners that work tactically with our founders to scale their businesses quickly and smartly. We connect the dots within the broader food & beverage ecosystem to provide unique access, share distinct expertise, and build solid infrastructure.

Related People